ABSTRACT
Lung cancer is the leading cause of cancer death among men in Spain 1 and ranks highest in both incidence and mortality in most parts of the world. In the United States, the 5-year overall survival rate is still around 16%. 2 Non-small cell lung carcinoma (NSCLC) accounts for almost 75% to 80% of lung cancers and represents a heterogeneous group of cancers consisting mainly of adenocarcinoma (ADC) (50%) and squamous cell carcinoma (SCC). The remaining 20% to 25% of the cases consist of small cell lung cancer (SCLC). NSCLC and SCLC are predominantly classified by morphology, and currently, no reliable tumor marker or blood test for lung cancer that might avoid the histopathologic Upon completion of this activity you will be able to:
• recognize erythrocyte fatty acid patterns in patients with different advanced types of lung cancer, chronic obstructive pulmonary disease (COPD), and asthma. • apply gas chromatography/mass spectrometry followed by receiver operating characteristic curve analysis in the interpretation of erythrocyte total fatty acid profiles in patients with lung cancer and benign lung diseases to reveal potential lung cancer biomarkers.
• discuss tumor marker levels of sialic acid and cytokeratins in advanced squamous cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma, COPD, and asthma.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
Questions appear on p 134. Exam is located at www.ascp.org/ajcpcme.
approach is available. Consequently, risky tumor biopsies are needed for examination, although easily accessible specimens such as blood products would be much more desirable. The actual technological revolution, driven not only by genomic and proteomic techniques but also by metabolomic and bioinformatic analyses, has catapulted researchers to search for new substances or parameters that could be used as tumor markers for neoplastic diseases in general. Undoubtedly, these investigations will help explore biomarkers and their use in the diagnosis, treatment, and prognosis of lung cancer in general and its different types in particular.
One of the most promising possibilities to adapt nonconventional technology to tumor marker research is metabolic profiling, which has been used increasingly as a probe in pharmacologic analysis and disease diagnosis. 3 Recently, plasma fatty acid metabolic profiling assessed by gas chromatography/mass spectrometry (GC/MS) has been used to detect biomarkers of hepatocellular carcinoma. 4 Several factors link lipids, blood, and blood cells and cancer. First, alterations in lipid and fatty acid metabolism in patients with cancer are well documented. [5] [6] [7] Second, essential polyunsaturated fatty acids (PUFAs), important molecules in complex metabolic reactions, appear to be critical targets in the complex metabolic stages that lead to or are associated with cancer. Finally, blood cells are significantly affected by malignant diseases, [8] [9] [10] including lung cancer. [11] [12] [13] In fact, two common complications in cancer, which are especially prevalent in patients with NSCLC, 14 are anemia and a prothrombotic state. In addition, a role of erythrocytes in inflammatory disease and, by extension, in malignancy has also been reported. 15 Also, hemostatic abnormalities in cancer are known, although their biological significance is unclear. 16 On the basis of all these facts, we have recently proposed that the analysis of erythrocyte and platelet fatty acid profiles might yield clinically useful patterns, with an ultimate goal the discovery of biomarkers or the construction of an additional test for the diagnosis and/or management of lung cancer. 17, 18 Nevertheless, the use of a blood cell fatty acid profile, especially that of erythrocytes, to distinguish different types of lung cancer and to discover some fatty acid species that might be used as a biomarker of specific lung cancers, has not been addressed, to our knowledge. Accordingly, in the present work, we analyzed the fatty acid profiles of total lipids in erythrocytes from patients with advanced lung ADC, lung SCC, and SCLC. As controls, healthy participants and patients with benign lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, were also enrolled in the study. The ultimate goal was to check which of those fatty acids might eventually be used as a biomarker of a specific lung cancer type. For comparison, we also examined two different kinds of serum molecules that have been proposed to be useful for the 
Materials and Methods

Study Design and Eligibility
The cohort investigated in this prospective study consisted of (1) 65 male and female current smokers with histologically confirmed primary NSCLC (30 SCC and 20 ADC) or SCLC (n = 15) according to the World Health Organization classification, (2) 17 male and female current smokers with COPD recruited during a moderate to severe exacerbation whose medication (b 2 agonists, anticholinergics, and inhaled corticosteroids) was suspended 12 hours before the procedure, (3) 19 male and female patients with asthma (no history of smoking) recruited during a moderate exacerbation (Global Initiative for Asthma guidelines) who underwent a complete clinical examination and chest x-ray to exclude the presence of concomitant acute illness such as pneumonia, and (4) 55 healthy male and female volunteers as controls, whose age, body weight, blood lipids, blood pressure, and body mass index were equivalent to those of the patient groups ❚Table 1❚ and whose smoking habits were similar to those of the patients with cancer or COPD (Table 1) . No further control group of nonsmokers was included in the study, because we have previously reported that no differences in erythrocyte lipids depending on smoking are detected in healthy subjects. 18 Regarding this, it has also been described that although smoking causes an increase in oxidative stress, the systemic oxidant/antioxidant imbalance in COPD is probably independent of smoking. 23 Eligibility criteria for the patients with cancer included the following: (1) no previous chemotherapy or radiotherapy; (2) Eastern Cooperative Oncology Group performance status of 2 or less; (3) adequate bone marrow, liver, renal, and cardiac function; (4) no known brain metastasis; and (5) no previous malignancy and no serious concurrent medical illness. All patients with cancer underwent a computed tomography (CT) scan of the chest and upper part of the abdomen, a bone scintigram, and a brain CT scan or magnetic resonance imaging. TNM staging (from the International Union Against Cancer) rendered nine, 15, and six; six, 10, and four; and three, four, and eight patients with SCC, ADC, and SCLC with stages IIIA, IIIB, and IV, respectively. The eligibility criteria for the patients with COPD included the following: (1) a forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (pulmonary function parameters measured with a Masterscreen Body spirometer [Jaeger, Würzburg, Germany]) ratio of less than 0.7 and an FEV 1 of less than 80% of the predicted value, (2) smoking history of more than 20 packyears, and (3) no history suggestive of asthma. The minimum criteria for the diagnosis of an asthma exacerbation included (1) intense subjective breathlessness, (2) audible wheezing on auscultation, and (3) a morning peak expiratory flow less than 70% of the personal best value. Blood samples were taken the day after the patients were informed of their illness (cancer) or at the time of consultation. None of the individuals had extreme dietary habits; they all lived in the same geographical area (Autonomous Regional Community of Castilla y León, Spain), and all followed a typical Mediterranean diet with a similar diet. In addition, all individuals were free of known diseases that might influence blood cell lipid contents 24, 25 or other symptoms that might reflect oxidative stress (anorexia/ cachexia, nausea, and vomiting). None of the individuals had received drugs that might interfere with erythrocyte functions within the 3 months preceding blood sampling. The survey was approved by the hospital and university institutional review boards, and participants were well informed of the purpose of the present study and gave verbal consent to participate in it.
Blood Sampling and Isolation of Serum, Plasma, and Erythrocytes
Two blood samples were drawn from all individuals. The first one was allowed to coagulate at room temperature to obtain the serum by centrifugation. The second sample was heparinized and used to obtain the erythrocytes and platelet-rich plasma after centrifugation at 1,000g for 5 minutes. Two-thirds of the platelet-rich plasma was then centrifuged at 2,600g for 10 minutes to obtain the plasma. Isolated erythrocytes were washed three times with three volumes of a solution of 876 mg/dL (150 mmol/L) NaCl and 69 mg/dL (5 mmol/L) sodium phosphate buffer, pH 8.0. The serum or plasma was stored at -80°C until tested. The b-thromboglobulin/platelet factor 4 (b-TG/PF4) ratio was not less than 2.5 in any sample, and hence incorrect sampling and manipulation of the blood withdrawn was ruled out. 26 
Biochemical Measurements in Serum and Plasma
b-TG and PF4 were measured in plasma with commercial enzyme-linked immunosorbent assay kits (Boehringer Mannheim Italy, Milan, Italy) according to the manufacturer's instructions. Each sample was analyzed in triplicate (coefficient of variance <10%). All samples were within the range of the calibration curves. Peaks were identified by their characteristic mass spectra on a coupled Shimadzu MS QP 5000 mass spectrometer. Analysis was performed in electron impact mode (ionization energy, 70eV; source temperature, 150°C). A calibration curve was obtained under the same experimental conditions with a standard FAME mixture (Supelco S37, SigmaAldrich, Madrid, Spain) to correct differences in the detector response. Fatty acids were expressed as percentages of total fatty acids (wt%). The calibration curves were linear in the range of lipid phosphorus analyzed (r > .99) and with coefficient of variance less than 5%.
Statistical Analyses
Considering that this was a pilot study with no previous hypothesis on results, the sample size was chosen as previously proposed, 31 and no statistical adjustment was considered to lead to fewer errors of interpretation. 32 Data were analyzed using the nonparametric Mann-Whitney U test. Differences were considered statistically significant when the P value was less than .05. The overall diagnostic performance or accuracy was assessed by calculation of the area under the receiver operating characteristic (ROC) curves (AUROC). AUROC can take any value between 0 and 1, and the closer it is to 1, the better the overall diagnostic performance of the test. A test with an AUROC curve value of 1 is perfectly accurate. 33 ROC curves were also used to select the cutoff level 34 for each tumor on the basis of the best accuracy. If several cutoff points had the same accuracy, the value with the best specificity was chosen. All statistical analyses were implemented using the SPSS program for Windows (version 17.0; SPSS, Chicago, IL). 35 
Results
No differences were found in plasma cholesterol, highdensity lipoprotein cholesterol, or triacylglycerol contents between patients and controls ( Table 1) .
Levels of Biomarkers in Serum
❚Table 2❚ shows the serum levels of the biomarkers sialic acid and the cytokeratins TPS and Cyfra 21-1 in control participants, patients with benign disease, and those with ADC, SCC, and SCLC. Compared with control participants, all sialic acid levels, except that of FSA, were significantly increased in all patients. Furthermore, cytokeratin markers were increased in patients with NSCLC (although only when they were not normalized by TP in patients with ADC) but not in patients with SCLC, probably due to the high variability shown in their values, as indicated by their standard deviation values (only Cyfra 21-1/TP almost reached significance: P < .051). Compared with patients with benign Sialic acids and cytokeratins were measured in serum as indicated before. 17, 18 FSA was determined according to the thiobarbituric acid method described by Aminoff. 27 TSA was quantified by the same procedure after hydrolysis of the samples in five volumes of 0.1N H 2 SO 4 at 80°C for 1 hour. BSA was calculated as the difference between TSA and FSA. Each sample was analyzed in triplicate (coefficient of variance <10%), and for each determination, spectrophotometric readings against blank were made at 549 and 532 nm to overcome interference from 2-deoxyd-ribose. The concentration of sialic acid was calculated using simultaneous equations as described by Warren. 28 The molecular extinction values for N-acetylneuraminic acid and 2-deoxy-d-ribose at 532 and 549 nm were calculated from calibration curves, obtained using different dilutions of the commercial products under similar experimental conditions. Cyfra 21-1 and TPS were measured using immunoradiometric assays (ELSA Cyfra 21-1 [CIS Biointernational, Gif-sur-Yvette Cedex, France] and TPS IRMA [Beki Diagnostics AB, Bromma, Sweden], respectively) at the Nuclear Medicine Service of the University Hospital of Salamanca following the quality standards of the service. Samples were analyzed in triplicate (coefficient of variance <8%). Serum protein contents (TP) were estimated by the Biuret method, 29 using bovine serum albumin as standard.
Lipid Extraction, Determination of Phospholipid Classes, and Fatty Acid Analyses
Total lipids were extracted from erythrocytes with mixtures of isopropanol/chloroform. 30 Then, cholesterol and phospholipids were determined in the lipid extracts. 30 Separation and quantification of the phospholipid classes were accomplished by two-dimensional thin-layer chromatography, followed by phosphorus determination after hydrolysis of the lipid spots with HClO 4 . 30 Fatty acid analyses were carried out by GC/MS 12, 13, 18, 30 at the Mass Spectrometry Service of the University of Salamanca, following all quality standards of the service. Aliquots of total lipid extracts (10-15 mg lipid phosphorus/sample) were transmethylated with BF3 reagent, and fatty acid methyl esters (FAME) were partitioned in a water/petroleum hydrocarbon system, brought to dryness under nitrogen, and dissolved in 10 mL of isooctane. 29 GC/ MS (triplicate determinations per sample) was performed on a Shimadzu 17A apparatus with a TR-Wax (30 m × 0.25 mm × 0.25 μm) capillary column connected to a Shimadzu MS QP 5000 (Shimadzu, Duisburg, Germany). GC was programmed under the following temperature gradient: initial time at 130°C for 3 minutes, 15°C/min from 130°C to 190°C, 2°C/min from 190°C to 230°C, and holding at 230°C for 23 minutes, with helium as the carrier gas. Injector and detector temperatures were 210°C and 240°C, respectively. disease, cytokeratin markers were the only biomarkers that showed clear significant differences in patients with lung cancer, although they were restricted to those with SCC. Sialic acids changed significantly in patients with ADC only when they were normalized by TP (although their absolute values almost reached significance: P < .057 for TSA and BSA). No significant differences were detected among different patients with lung cancer.
Erythrocyte Lipids and Profiles of Total Lipid Fatty Acids
No differences were found either in erythrocyte cholesterol or phospholipids or in the percentage contents of the main phospholipid species from erythrocytes in the different pathologies analyzed ❚Table 3❚. Nevertheless, the fatty acid profile of total lipids from erythrocytes changed significantly in the different pathologies analyzed. ❚Table 4❚ shows the erythrocyte total fatty acids that provided a real positive state for one type of lung cancer (fatty acids that changed specifically in patients with one type of lung cancer vs the rest of the population, including healthy participants and individuals with benign lung diseases, as indicated in ❚Table 5❚). Among the main fatty acids, (1) 18:0 fatty acid increased significantly in patients with NSCLC (both ADC and SCC) but not in those with SCLC vs the control group; the increase was also significant in the SCC vs the benign group, as well as in the NSCLC (both ADC and SCC) vs the SCLC groups, although the fatty acid remained unchanged in the ADC vs the SCC groups. (2) 
ROC Curves for Biomarkers in Serum and Total Fatty Acids
We next calculated ROC curves for the erythrocyte total fatty acids shown in Table 4 Values are given as mean ± SD. Significance: vs controls: a P < .0001, b P < .001, c P < .002, d P < .003, e P < .006, f P < .008, g P < .034, h P < .037; vs benign: i P < .0001, j P < .020, k P < .025.
state for one type of lung cancer (fatty acids that changed specifically in patients with one type of lung cancer vs the rest of the population, including healthy participants and individuals with benign lung diseases), as well as for the tumor markers ( . Fatty acids are expressed as percentages of total fatty acids. Significance: vs controls: a P < .0001, b P < .001, c P < .002, d P < .005, e P < .014, f P < .025, g P < .031, h P < .039, i P < .041, j P < .048; vs benign: k P < .0001, l P < .001, m P < .008, n P < .011, o P < .019, p P < .05; vs adenocarcinoma: q P < .0001, r P < .001, s P < .002, t P < .01, u P < .031, v P < .041, x P < .05; vs squamous cell carcinoma: y P < .018, z P < .038. FSA, free sialic acid; ROC, receiver operating characteristic; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; TP, total protein; TPS, tissue polypeptide-specific antigen; TSA, total sialic acid. a Only fatty acids whose real positive state is one of the cancer types (they reveal changes in patients with one type of cancer vs the rest of the population, including healthy participants and patients with benign disease) are shown. CI for accuracy refers to the range of values containing the true accuracy of the population considered, with a probability of 95%.
physiologic levels (see Table 5 ). Regarding serum markers, for ADC and with respect to the sialic acids, both TSA and BSA showed the same specificity, sensitivity, and accuracy values (66%, 64%, and 65%, respectively). Also, when sialic acids were normalized by TP, the specificity and accuracy increased (74% and 72% for TSA/TP and 75% and 71% for BSA/TP), while sensitivity decreased to 50% only for BSA/TP. We also found positive correlations among TSA, BSA, TSA/TP, and BSA/TP (data not shown); for example, between TSA and BSA, we found Spearman correlation coefficients of 0.999 (P < .0001), 1 (P < .0001), 1 (P < .0001), 0.994 (P < .0001), 1 (P < .0001), and 0.999 (P < .0001) or 0.994 (P < .0001), 0.859 (P < .0001), 1 (P < .0001), 0.997 (P < .0001), 0.994 (P < .0001), and 0.994 (P < .0001) for ADC, SCC, SCLC, COPD, asthma, and control groups when TSA and BSA values were not normalized or normalized by TP, respectively. The cytokeratin Cyfra 21-1 showed significantly higher values than did TPS for ADC (92%, 67%, and 84% vs 70%, 66%, and 68% in specificity, sensitivity, and accuracy, respectively). It has been reported that the correlation index between the cytokeratins TPA and Cyfra 21-1 is high. 22 Here we found a positive correlation between the two cytokeratin markers TPS and Cyfra 21-1; for example, in the SCC group, we found Spearman correlation coefficients of 0.532 (P < .009) and 0.625 (P < .001) when the markers for SCC. Neither tumor marker showed a real positive state for patients with SCLC. Regarding erythrocyte total fatty acids, different species showed real positive states for specific types of lung cancer, including SCLC. In fact, the diagnostic accuracy of several was similar to or greater than that of sialic acid (0.69 for TSA or BSA in ADC) or cytokeratins (0.69 and 0.81 for TPS and Cyfra 21-1 in SCC, respectively). The most significant were ADC, 20:4n6 (0.81); SCC, 18:2n6 (0.73); and SCLC, 18:0 (0.70) and 22:4n6 (0.63). Importantly, at least one major fatty acid in cells had high diagnostic accuracy in every type of lung cancer analyzed. The operating characteristics for the individual fatty acids and tumor markers (shown in Table 5 ) with their cutoff points for achieving the best individual accuracy are shown in ❚Table 6❚. The highest specificity, sensitivity, and accuracy were found for the following: (1) 20:4n6, 20:2n6, and 22:2 fatty acids (78%, 75%, and 77%; 94%, 67%, and 91%; and 97%, 58%, and 93%, respectively) for ADC; (2) 17:1, 18:2n6, and 22:0 fatty acids (66%, 77%, and 70%; 64%, 71%, and 66%; and 67%, 66%, and 67%, respectively) for SCC; and (3) 18:0, 18:1n9, and 22:4n6 (69%, 71%, and 69%; 61%, 57%, and 61%; and 79%, 57%, and 78%, respectively) for SCLC. In addition, 17:0, although showing 96% specificity, had only 43% sensitivity, with an excessively high cutoff point in comparison with normal or biomarkers. The comparison of the specific total fatty acids that showed a real positive state in lung ADC, SCC, and SCLC (see Tables 5 and 6 ) with other established serum markers, such as sialic acid and TPS and Cyfra 21-1 (soluble degradation products of cytokeratins), by analysis of their operating characteristics, led us to detect some potentially useful fatty acid markers. Importantly, at least one of the main fatty acids might be used as a biomarker for every type of lung cancer. For ADC, SCC, and SCLC, arachidonic acid (AA, 20:4n6), linoleic acid (LA, 18:2n6), and stearic acid (SA, 18:0), respectively, were the most significant because they represent major fatty acids that decrease in each disease, and their diagnostic accuracy and operating characteristics were similar to those of the established serum markers. The fatty acid changes found in the present study do not seem to be a consequence of diet or different diseases, factors that are able to modify the chemical composition of blood cells (see "Study Design and Eligibility"). Besides, no differences were detected in either erythrocyte cholesterol or phospholipids. Accordingly, we suggest that they would be related to the neoplastic disease itself or to the generalized inflammation that accompanies the phenomenon of carcinogenesis.
AA, LA, and SA are all very important bioactive molecules that can act as an energy source as nutrients or function as signaling molecules in several cellular processes. It is known that the metabolism of different essential fatty acids is altered in several diseases, including cancer. 45 LA is a precursor of AA, and both are essential n-6 fatty acids whose deficiency is rare in humans. 45 Both fatty acids are important structural constituents of all cell membranes that influence membrane fluidity as well as membrane-bound enzymes and receptor behavior. LA also influences gene expression. 45 AA is released from membranes and then converted into lipid mediators (prostaglandins, thromboxanes, and leukotrienes) by both the lipoxygenase and cyclooxygenase pathways. These mediators have proinflammatory and angiogenic actions and are known to be involved in several pathologic processes, such as atherosclerosis, asthma, and several other inflammatory conditions. 45 Moreover, AA metabolism plays a role in the cell-matrix interactions and the integrin signaling that occur in metastasis. 46 Nevertheless, the association between AA exposure and risk of cancer is highly controversial. 47 The PUFA depletion observed here seems not to be due to the action of phospholipase A 2 because the phospholipid profiles remained unchanged, with no significant appearance of lysophospholipids. By contrast, PUFA depletion might be due at least in part to changes in desaturases, as have been proposed to occur in cancer, 7 or might be the result of the lipid peroxidation processes that also occur in cancer. 12, 13 In this regard, both benign inflammatory diseases (such as COPD and asthma) and carcinogenesis are characterized not only by a generalized inflammatory disorder that is commonly were normalized or not normalized by TP, respectively. No correlation was found between either of the cytokeratins and the sialic acid values.
According to the data shown in Table 6 , when the diagnostic yields (sensitivity and specificity) were analyzed at the cutoff point to achieve the best accuracy, some total fatty acids showed similar or even higher values than cytokeratins or sialic acids.
Discussion
Lung serum tumor markers, including a heterogeneous group of substances, are widely used in several clinical applications such as screening, diagnosis, and prognosis to evaluate the effectiveness of treatments or to monitor for recurrence after therapy, although high concentrations of these markers are mainly found in advanced and many times incurable disease stages. Our understanding of the cellular processes that become altered in lung cancer allows the onset of potential new biomarkers of the disease. In this sense, it is well known that abnormal metabolism is a cancer hallmark, resulting from changes in many different parameters in different cell types during cancerous processes. 36 Also, metabolomics, and specifically fatty acid profiling, has been used increasingly in many fields, including disease diagnosis and biomarker screening 4, 37 and, more specifically, lung cancer diagnosis. 38 It is known that the integrity and function of erythrocytes are altered in human pathologies, sharing redox alterations as a hallmark. [39] [40] [41] In addition, changes in the fatty acid composition of different blood cell fatty lipids (including erythrocytes) in patients with different types of cancer, 7, 42 including lung cancer, 12, 17, 18, 43 have been reported. Also, it was previously proposed that one of the cellular biomarkers with diagnostic or prognostic value in different inflammationrelated diseases would be the structure and function of erythrocytes, 44 in part due to the long half-life (120 days) of erythrocytes, which make them appropriate for investigating the relations of the patterns of fatty acids and cancer. The paradigm of these kinds of pathologies is COPD, and it is known that inflammation may be the link between COPD and lung cancer, one of the main complications of COPD. 44 We have proposed that the analysis of erythrocyte fatty acid profiles might be a strategy in the discovery of biomarkers or the construction of an additional test for the diagnosis and/or management of lung cancer, 17, 18 although to our knowledge, the use of these fatty acid profiles with specific lung cancers has not been addressed. Accordingly, in the present work, we analyzed the fatty acid profiles of total lipids in erythrocytes from patients with advanced lung ADC, lung SCC, and SCLC and other patients with benign inflammatory lung diseases (COPD and asthma) to detect potential fatty acids that could eventually be used as observed in patients with cancer in general, and lung cancer in particular, but also by systemic oxidative stress. Recently, by using GC/MS, it has been reported that human lung ADC is associated with increases in plasma LA, which might be related to the imbalance in the redox systems associated with the neoplasm. 38 The high specificity of the decrease of at least LA in erythrocytes observed in this work further highlights its potential use as a biomarker, because it was not detected in the blood cells from patients with benign inflammatory diseases of the lung such as asthma or COPD. This is also important because the latter sometimes culminates in lung cancer.
With respect to the cytokeratin markers, it has been reported that Cyfra 21-1 affords higher accuracy in comparison with TPS in both SCLC and NSCLC. 48 In the present work, we observed that cytokeratins showed a real positive state for SCC. In this case, Cyfra 21-1 showed greater diagnostic accuracy (AUROC curve) and, at the best cutoff point, better specificity and accuracy, although with a sensitivity similar to that shown by TPS. Recently, it has been proposed that although Cyfra 21-1 levels might be high in patients with benign lung diseases, cytokeratin levels greater than twice the standard cutoff level suggest a high possibility of advanced lung cancer. 49 Regarding sialic acids, it has been reported that TSA levels are not altered by smoking, 19 one of the main causes of lung cancer. 21 Nevertheless, it is known that TSA and BSA are increased in a variety of tumors, including lung cancer. 50 The main problem of TSA and BSA as biomarkers is that although they are highly sensitive markers of lung cancer, their specificity is low. 51 Nevertheless, they can be used in monitoring responses to treatment in patients and in detecting recurrence in a variety of tumors, including lung carcinoma. 51 In the present work, we observed that sialic acids showed a real positive state only for ADC. At the designated cutoff levels used in this work (chosen on the basis of the highest accuracy), the specificity of TSA or BSA was higher when they were normalized by TP, as already reported. 52 Collectively, our data show that at least one of the main fatty acids from erythrocyte total phospholipids is a potential biomarker of the different types of lung cancer: ADC, SCC, and SCLC. This fact has led us to investigate the aspects of the clinical practice or the disease process in which its determination would be more valuable. In addition, it will be interesting to check whether the operating characteristics of the potential biomarkers detected here could provide useful tools to discriminate the stage of the disease. Also, it will be necessary, from a statistical point of view, to use complex multivariate approaches 4 in larger samples to improve the reliability of the fatty acid tumor biomarkers found in this work using ROC operating characteristics.
